This study is a prospective, single-center, observational study. In this study, we aim to evaluate the clinical outcome and cost-effectiveness of different treatments of lower extremity arterial occlusive disease. It is expected to include about 400 patients diagnosed with lower extremity arterial occlusive disease in our center from July 2024 to July 2026. All enrolled patients will be followed for three years. All patients diagnosed with arteriosclerosis obliterans (ASO) and all treatment techniques were included in this study. The primary outcomes include the Efficacy and Safety End Points of each techniques.
Age 18 years or older, gender is not limited.
Patients diagnosed with arteriosclerosis obliterans.
Rutherford stages 2-6.
When there are multiple stenosis lesions, the treatment of the most severe lesion is included.
Malignant tumor
Alzheimer's disease
Blood disease or bleeding tendency
Heart Failure Grade III ~ IV
6
Treatment groupsSee each treatment group below.